CRP and rheumatoid arthritis: These mechanisms may elucidate the improved, yet modest overall, RA disease activity, swollen joint scores, and reduced CRP in the TARA (Trial of Atorvastatin in Rheumatoid Arthritis) trial, a 6-mo, placebo-controlled, randomized clinical trial with Atorvastatin [6].